Abstract:Background: Mucorales infections continue to cause significant morbidity and mortality in immunocompromised hosts despite the advent of new approaches for diagnosis and treatment of fungal infections. We aimed to evaluate risk factors and outcomes of Mucorales infection in solid organ transplant, hematopoietic cell transplant, and chimeric antigen receptor T-cell therapy recipients. Methods: This single-center retrospective study included solid organ transplant, hematopoietic cell transplant, and chimeric antigen receptor T-cell patients with cultures positive for Mucorales. Results: Forty-three patients were included for analysis; 34 solid organ transplant (79%) and 9 hematopoietic stem cell transplant or chimeric antigen receptor T-cell (21%). Infection with Mucorales occurred a median of 184 days after transplant. At the time of diagnosis, 36 patients were on antifungal prophylaxis with the majority receiving posaconazole (53%). Thirty-three had clinically significant disease; 30 received definitive anti-Mucorales therapy and 3 empiric antifungal therapy. Isavuconazole was the most common azole used for treatment in monotherapy recipients. All-cause mortality was 64% and, of these deaths, 18 (75%) were directly related to Mucormycosis. The highest mortality was seen in disseminated and intra-abdominal disease (100%), followed by pulmonary disease (50%). There was no significant association with mortality and transplant type or number of immunosuppressive agents. Conclusion: Mucormycosis is an important cause of morbidity and mortality in immunocompromised patients. Breakthrough infection was not uncommon in this study. Data regarding the incidence of infection at approximately 6 months after transplantation can inform prophylaxis and treatment regimens. The spectrum of antifungal regimens used reflects the lack of consensus on ideal regimens for these organisms and a need for more studies.

Prospective antifungal therapy (PATH) alliance®: focus on mucormycosis

[Clinical High Risk Factors and Prognosis of 25 Pulmonary Mucormycosis Cases].

Mucormycosis in Renal Transplant Recipients: Review of 174 Reported Cases.

Risk Factors and Outcomes of Mucorales Infection in a Modern Cohort of Solid Organ Transplant, Hematopoietic Cell Transplant, and Chimeric Antigen Receptor T-cell Therapy Recipients

Clinical Characteristics, Prognosis Factors and Metagenomic Next-Generation Sequencing Diagnosis of Mucormycosis in patients With Hematologic Diseases

Fatal Gastrointestinal Mucormycosis in an Immunocompetent Patient : a Case Report and Review of the Literature

Pathogenesis of mucormycosis

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study

How I treat mucormycosis

Epidemiology, clinical manifestations, and outcome of mucormycosis in solid organ transplant recipients: a systematic review of reported cases

Combination therapy for mucormycosis: why, what, and how?

Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens

Epidemiology and treatment of mucormycosis

Mucormycosis in children with cancer and hematopoietic cell transplant—A single center cohort study

Mucormycosis treatment: Recommendations, latest advances, and perspectives

Metagenomic Next-Generation Sequencing for Diagnostically Challenging Mucormycosis in Patients with Hematological Malignancies

Recent advances in the management of mucormycosis: from bench to bedside

Pulmonary mucormycosis

Mucormycosis: A Case Series

Mucormycosis caused by unusual mucormycetes, non-Rhizopus,-Mucor, and-Lichtheimia species

Future directions in mucormycosis research